3.69

1.74% -0.04

Zentalis Pharmaceuticals Inc (ZNTL)

Overview News Price History Option Chain Financials Why ZNTL Down? Discussions Forecast

Zentalis Pharmaceuticals Inc stock is traded at $3.69, with a volume of 659.56K. It is down -1.74% in the last 24 hours and up +8.75% over the past month. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Previous Close:

$3.73

Open:

$3.62

24h Volume:

659.56K

Relative Volume:

0.35

Market Cap:

$265.23M

Revenue:

Net Income/Loss:

$-292.19M

P/E Ratio:

-0.7688

EPS:

-4.8

Net Cash Flow:

$-208.41M

1W Performance:

+29.05%

1M Performance:

+8.75%

6M Performance:

-68.70%

1Y Performance:

-79.50%

1-Day Range:

$3.46

$3.75

1-Week Range:

$2.66

$4.07

52-Week Range:

$2.66

$18.24

Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile

Name

Zentalis Pharmaceuticals Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(858) 263-4333

Address

10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY

Employee

168

Twitter

@ZentalisP

Next Earnings Date

2024-11-04

Latest SEC Filings

ZNTL's Discussions on Twitter

Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-12-22	Initiated	Cowen	Outperform
Apr-06-22	Initiated	Wells Fargo	Overweight
Oct-07-21	Resumed	Jefferies	Buy
Sep-30-21	Initiated	Stifel	Buy
Sep-29-21	Initiated	Oppenheimer	Outperform
May-21-21	Initiated	UBS	Buy
Jan-20-21	Initiated	Wedbush	Outperform
Sep-29-20	Initiated	Cantor Fitzgerald	Overweight
Aug-27-20	Initiated	H.C. Wainwright	Buy
Apr-28-20	Initiated	Guggenheim	Buy
Apr-28-20	Initiated	Jefferies	Buy
Apr-28-20	Initiated	Morgan Stanley	Overweight
Apr-28-20	Initiated	SVB Leerink	Outperform

View All

Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News

04:03 AM

Vanguard Group Inc's Strategic Reduction in Zentalis Pharmaceuti - GuruFocus.com

04:03 AM

Nov 04, 2024

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Hold" by Brokerages - MarketBeat

Nov 04, 2024

Nov 01, 2024

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024

Oct 31, 2024

Immunome (NASDAQ: IMNM) Acquires Zentalis Pharmaceuticals’ Licensed Assets IMMUNOME, Inc. made a recent significant move on October 25, 2024, by acquiring Zentalis Pharmaceuticals, Inc.’s Licensed Assets. This acquisition was carried out thr - Defense World

Oct 31, 2024

Oct 26, 2024

Zentalis stock hits 52-week low at $2.82 amid market challenges - Investing.com Canada

Oct 26, 2024

Oct 18, 2024

State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings - Yahoo Finance

Oct 18, 2024

Oct 16, 2024

Perhaps timely catching Zentalis Pharmaceuticals Inc (ZNTL) would be a good idea - SETE News

Oct 16, 2024

Oct 15, 2024